Marinus Pharmaceuticals Comments On Ovid Therapeutics' Patent Challenge And Provides Update On Marinus' Post Grant Review
affirmed its commitment to defending its patent portfolio amidst an Inter Partes Review (IPR) challenge of U.S. Patent 11,110,100 from Ovid Therapeutics, Inc. filed on March 26, 2024. This challenge r
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review
Over the past two decades, Marinus has invested more than $100 million into our ganaxolone development programs in SE," stated Dr. Scott Braunstein, Chairman and CEO of Marinus.
Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights
Throughout the last three months, 4 analysts have evaluated Marinus Pharma (NASDAQ:MRNS), offering a diverse set of opinions from bullish to bearish.The following table encapsulates their recent ratin
Buy Rating Affirmed for Marinus Pharmaceuticals With Promising Outlook for Ganaxolone in RSE Treatment
Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
Marinus Pharmaceuticals (NASDAQ:MRNS) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency
Marinus Pharmaceuticals' (MRNS) Ztalmy was approved by the UK Medicines and Healthcare products Regulatory Agency on Thursday for the treatment of seizures in patients with cyclin-dependent kinase-lik
UK Approves Marinus Pharmaceuticals' Ztalmy for Rare Genetic Disorder
The UK Medicines and Healthcare products Regulatory Agency approved Marinus Pharmaceuticals' Ztalmy for the treatment of cyclin-dependent kinase-like 5 deficiency disorder, a rare genetic disorder. Th
Marinus Pharmaceuticals Is Maintained at Perform by Oppenheimer
Marinus Pharmaceuticals Is Maintained at Perform by Oppenheimer
Express News | Oppenheimer Maintains Perform on Marinus Pharma, Maintains $9 Price Target
Marinus Pharmaceuticals Earns Buy Rating From Analyst on Strong Sales and Promising Pipeline
Earnings Call: Marinus Pharmaceuticals Anticipates Profitability in Q2 2024
The company has also seen progress with its commercial partners in the EU, China, and MENA regions, which are aiding in the global launch of ZTALMY.
Marinus Pharmaceuticals Price Target Maintained With a $24.00/Share by RBC Capital
Marinus Pharmaceuticals Price Target Maintained With a $24.00/Share by RBC Capital
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Health care stocks were edging higher premarket Wednesday with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) recently advancing by 0.5%. Grifols (GRFS)
Express News | HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Marinus Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 217.65% HC Wainwright & Co. → $27 Reiterates Buy → Buy 12/05/2023 217.65% HC Wainwright & Co. →
Update: Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket
(Updates with the stock move in the headline and the first paragraph.) Marinus Pharmaceuticals (MRNS) shares slumped 8% in premarket activity on Wednesday after the company reported a wider-than-antic
Optimistic Buy Rating for Marinus Pharmaceuticals Based on Promising Clinical Trials and NDA Potential
Earnings Call Summary | Marinus Pharmaceuticals(MRNS.US) Q4 2023 Earnings Conference
The following is a summary of the Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript:Financial Performance:Marinus reported full year 2023 net product revenue of $19.6 million, with
No Data